GLOW vs KLOW: Is the Fourth Peptide Worth It?
GLOW and KLOW are marketing names commonly separated by the addition of KPV. Compare their nominal labels and the actual component evidence without assuming that one is an upgrade, clinically complete or interchangeable with the other.
Side by Side
| Comparison | GLOW | KLOW |
|---|---|---|
| Components | GHK-Cu, TB-500, BPC-157 | GHK-Cu, TB-500, BPC-157, KPV |
| Standard vial | Advertised 70 mg (50 / 10 / 10) | Advertised 80 mg (50 / 10 / 10 / 10) |
| GHK-Cu fraction | 50 mg | 50 mg |
| Primary target | Marketed for skin, hair and repair; not established blend outcomes | Adds marketed inflammation goals; no established added human benefit |
| Typical dose basis | Online total-blend figures; not validated dosing | Online GHK-Cu-content figures; not validated dosing |
| Cost per mg | Needs matched, current offers | Needs matched, current offers |
| Human trial of the blend | None identified in assessed sources | None identified in assessed sources |
| Route | No route validated by a human blend trial | No route validated by a human blend trial |
| Regulatory status | Not FDA-approved | Not FDA-approved |
| Dosing flexibility | Fixed ratio, no independent adjustment | Fixed ratio, no independent adjustment |
Full component guides: GLOW, KLOW, GHK-Cu, TB-500, BPC-157, and KPV.
What KPV Actually Adds
KPV is lysine-proline-valine from the end of alpha-MSH. Experimental inflammatory signaling is a rationale to investigate it, not proof that adding an anti-inflammatory ingredient improves tissue repair or is inert for other goals.
The KPV cell and mouse-colitis study found favorable inflammatory outcomes in human-derived cells and mouse colitis. The 2026 engineered proKPV study concerns an engineered oral delivery conjugate in preclinical models, not a standard KPV capsule or KLOW injection. These positive findings support research without establishing human symptom relief.
Related reading: BPC-157 vs KPV comparison.
Dosing: The Trap When Switching Between Them
Online figures sometimes describe GLOW by total blend mass and KLOW by GHK-Cu-equivalent content. These are different quantities. Neither is a validated dose or switching schedule, and a syringe-unit number also depends on exact concentration.
For the nominal 50/10/10 and 50/10/10/10 labels, equal total blend mass gives different component amounts; matching GHK-Cu mass is another arithmetic comparison. Neither establishes equal elemental-copper dose, absorbed exposure or safety. No mixing volume or administration instruction follows from this arithmetic.
Related reading: reconstitution guide; GHK-Cu dosing.
Human Blend Evidence and Component Findings
No published human trial of either named blend was identified in the assessed evidence. Favorable component findings remain useful but differ in molecule, route, formulation and endpoints.
A 1994 topical GHK-Cu trial reported median plantar-ulcer area closure of 98.5% versus 60.8% with vehicle alongside standardized wound care. This is a favorable topical-formulation finding, not a percentage of patients cured or evidence for an injected blend.
The 2021 knee-pain report reported symptom improvement after intra-articular treatment in 11 of 12 contacted BPC-only recipients and three of four receiving BPC plus TB4, without a control or validated structural endpoint. The 2026 rat tendon experiment tested 32 rats after surgically repaired Achilles transection with 30 days of intraperitoneal treatment. TB-500 improved breaking load; BPC-157 had selected collagen findings but no significant breaking-load or total Bonar/Movin score improvement. The combination improved Movin score versus control without outperforming the individual treatments. Neither tests GLOW or KLOW.
The 2012 TB-500 chemical analysis identified Ac-LKKTETQ in the tested TB-500-labeled material. Full-length thymosin beta-4 trial findings cannot be assigned to that fragment or every marketed vial.
Related reading: are peptides safe; peptide side effects.
Cost: Per Milligram vs Per Useful Dose
No matched current vendor price dataset was established here. A comparison must match declared identity, amount, analytical scope, shipping and total cost; ingredient count does not determine delivered price.
A cost per clinically useful dose cannot be established without a validated effective dose. KPV is neither proven beneficial nor proven inert for an individual goal. Separate products can cost more or less; convenience and fewer transactions are not evidence of equivalent safety or treatment effect.
Related reading: buying peptides online safely; peptide therapy cost.
Which to Choose
There is no validated human selection rule that assigns GLOW to skin or tendon goals and KLOW to gut or immune conditions. The assessed sources do not establish a favorable benefit-risk balance for either blend in those populations.
A fixed ratio limits independent adjustment; separate materials change that arithmetic without establishing safe or effective combination treatment. Persistent skin, hair, injury or gastrointestinal concerns need condition-specific assessment rather than a blend-tier decision.
Neither commercial blend is an FDA-approved drug. Favorable July 2026 advisory recommendations are relevant policy developments, but a vote does not approve a blend or establish that a particular pharmacy preparation meets compounding requirements.
FDA’s May 14, 2026 category update restored GHK-Cu except injectable routes to Category 1. That route-specific development cannot authorize an injectable mixture. FDA’s safety and withdrawn-nomination page distinguishes withdrawn nominations from current Category 2 entries; withdrawal itself is not approval or proof of safety. No fixed rulemaking deadline or blanket permission is inferred here.
Related reading: the BPC-157 and TB-500 blend; best peptides for healing.
Frequently Asked Questions
KLOW-labeled products commonly add KPV to the GHK-Cu, TB-500 and BPC-157 ingredients of GLOW. The often-advertised examples total 70 mg (50/10/10) and 80 mg (50/10/10/10). Names and nominal ratios do not establish identity, handling, absorption or interchangeability.
No human head-to-head benefit is established. KPV has favorable preclinical inflammatory findings, but neither added benefit nor absence of benefit for a specific human goal is demonstrated by those findings.
No validated equivalent doses are established. Online GLOW and KLOW numbers use different bases, sometimes total-blend mass and sometimes GHK-Cu content. Both require the exact composition and concentration for arithmetic; neither supplies a proven safe administration schedule.
No matched current price comparison was established here. Compare the same declared identity, quantity, analytical scope and delivered cost. A cost per effective clinical dose cannot be calculated without a validated effective dose, and a fourth ingredient is not proven useful or inert for an individual.
No published human trial of either named blend was identified in the assessed evidence. Individual-component research includes positive topical GHK-Cu findings, small uncontrolled BPC-157 observations and preclinical KPV work. Those are distinct from blend efficacy or a head-to-head comparison.
Availability of separate KPV products does not establish human oral or injectable benefit. Separate quantities are adjustable in principle, but switching routes or combining products needs its own evidence; neither approach is proven clinically superior or safer here.
Equal labeled GHK-Cu amounts describe nominal complex mass, not elemental-copper dose or absorbed copper exposure. Formulation, identity, actual content and route matter. A label-based conversion cannot establish equivalent safety or a switching protocol.
Neither blend is FDA-approved. Eligibility for a particular compounded preparation depends on ingredient, route and applicable requirements. A favorable advisory vote, withdrawn nomination or research label does not approve either mixture or establish interchangeable legal status.
Updated October 27, 2026. Labels, component research and online conventions are distinct from validated blend treatment, preparation and safety evidence.